» Articles » PMID: 32983995

MiR-452 Reverses Abnormal Glycosylation Modification of ERα and Estrogen Resistance in TNBC (Triple-Negative Breast Cancer) Through Targeting UGT1A1

Overview
Journal Front Oncol
Specialty Oncology
Date 2020 Sep 28
PMID 32983995
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The breast epithelial cells in patients with triple-negative breast cancer (TNBC) actually have specific estrogen receptor (ER) expression, and the abnormal glycosylation of UGT1A1 in TNBC cells resulted in abnormal expression and function of ERα through regulating the modification of ERα. Therefore, our study targets the role of UGT1A1 expression, then glycosylation modification of ERα (estrogen receptor α) and estrogen resistance in development of TNBC. The differential expression of mRNA and miRNA in TNBC tissues was tested. Luciferase activity was analyzed in TNBC cells treated with miR-452. Moreover, the human mammary gland and TNBC cell lines were dealt with estrogen and miR-452 or its inhibitors, then proliferation ability was further determined. Moreover, the role of interaction between UGT1A1 and ERα in the glycosylation modification of ERα and UGT activity, and metabolism of estrogen were assessed. The effects of miR-452 on TNBC by improving abnormal glycosylation modification of ERα by targeting UGT1A1 and estrogen resistance were studied and . The expression level of UGT1A1 in TNBC tumor tissues was higher than its matched para-tumorous tissues, but the miR-452 expression was opposite. The glycosylation modification site of ERα expressed in TNBC cells was different from that of normal mammary epithelial cells. The estrogen 17β-estradiol (E2) significantly promoted mitotic entry of TNBC cells. The interaction between UGT1A1 and ERα affected the expression level of each other, as well as the UGT enzyme activity and proliferation of TNBC cells. UGT1A1 induced production of intracellular estrogens and TNBC proliferation, but it could be reversed by overexpression of ERα. Upregulation of ERα caused the downregulation of UGT1A1 and marked decrease of intracellular estrogen products, and then suppressed TNBC proliferation. Moreover, UGT1A1 was the target gene of miR-452; miR-452 antagomir restrained TNBC xenograft. Our results demonstrated that estrogen was a positive factor in the proliferation of TNBC cells at onset of mitosis through accentuating the expression and enzyme activity of UGT1A1. However, miR-452 targeted to UGT1A1, then regulated glycosylation modification of ERα, estrogen metabolism, and TNBC development associated with estrogen resistance.

Citing Articles

Roles of estrogen receptor α in endometrial carcinoma (Review).

Ge Y, Ni X, Li J, Ye M, Jin X Oncol Lett. 2023; 26(6):530.

PMID: 38020303 PMC: 10644365. DOI: 10.3892/ol.2023.14117.


Advances in drug resistance of triple negative breast cancer caused by pregnane X receptor.

Rao Z, Tang Z, Wen J World J Clin Oncol. 2023; 14(9):335-342.

PMID: 37771631 PMC: 10523191. DOI: 10.5306/wjco.v14.i9.335.


MicroRNA-452: a double-edged sword in multiple human cancers.

Dermani F, Datta I, Khoei S Clin Transl Oncol. 2023; 25(5):1189-1206.

PMID: 36622551 DOI: 10.1007/s12094-022-03041-0.


LINC01140 Targeting miR-452-5p/RGS2 Pathway to Attenuate Breast Cancer Tumorigenesis.

Li X Dis Markers. 2022; 2022:2434938.

PMID: 36299824 PMC: 9592237. DOI: 10.1155/2022/2434938.


Concanavalin A inhibits human liver cancer cell migration by regulating F-actin redistribution and assembly via MAPK signaling pathway.

Jiang H, Wen X, Zhang X, Zhang B Oncol Lett. 2022; 24(5):405.

PMID: 36276493 PMC: 9533664. DOI: 10.3892/ol.2022.13525.


References
1.
Liu F, Xu K, Xu Z, Rivas M, Wang C, Li X . The small molecule luteolin inhibits -acetyl-α-galactosaminyltransferases and reduces mucin-type -glycosylation of amyloid precursor protein. J Biol Chem. 2017; 292(52):21304-21319. PMC: 5766936. DOI: 10.1074/jbc.M117.814202. View

2.
Tukey R, Strassburg C . Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol. 2001; 59(3):405-14. DOI: 10.1124/mol.59.3.405. View

3.
Robinson M, Smyth G . Moderated statistical tests for assessing differences in tag abundance. Bioinformatics. 2007; 23(21):2881-7. DOI: 10.1093/bioinformatics/btm453. View

4.
Lonning P, Ekse D . A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochem Mol Biol. 1995; 55(3-4):409-12. DOI: 10.1016/0960-0760(95)00180-8. View

5.
Robson M, Im S, Senkus E, Xu B, Domchek S, Masuda N . Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017; 377(6):523-533. DOI: 10.1056/NEJMoa1706450. View